Clinical Trials
186 trialsIsa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
EMBRACE
Ontario Clinical Oncology Group (OCOG)
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Wake Forest University Health Sciences
SELVEDge
University of Miami
SL4903
Institute of Hematology & Blood Diseases Hospital, China
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Massachusetts General Hospital
Mezi-KD
Assistance Publique - Hôpitaux de Paris
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Massachusetts General Hospital
ISABELA
Massachusetts General Hospital
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Icahn School of Medicine at Mount Sinai
MUKEight
University of Leeds
TOMMY
Institut Cancerologie de l'Ouest
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Beijing GoBroad Hospital
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Beijing GoBroad Hospital
PCD
Institut Curie
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Massachusetts General Hospital
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University
YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
CAR19BCMA
Chinese PLA General Hospital
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Seoul St. Mary's Hospital
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Hadassah Medical Organization
MMRF Molecular Profiling Protocol
Multiple Myeloma Research Foundation
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
TALIM
Gruppo Italiano Malattie EMatologiche dell'Adulto
Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma
Duke University
FREEDOM
Assistance Publique - Hôpitaux de Paris
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
CONFIRM
Assistance Publique - Hôpitaux de Paris
MUKseven
University of Leeds
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
University of Pittsburgh
BMT-03
University of Illinois at Chicago
A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression
Peter MacCallum Cancer Centre, Australia
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Xiamen University
DARE
Hellenic Society of Hematology
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital
MUKtwelve
University of Leeds
GMMG-BIRMA
University of Heidelberg Medical Center
MM FPBMC
University of Virginia
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Zhejiang University
Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy
University of California, San Francisco